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Case Report
Successful Use of Rituximab for Hydralazine-Induced Anti-Neutrophil
Cytoplasmic Antibodies-Associated Vasculitis
Michael A. Paley1, Fahad Edrees2, Satoru Kudose3, Joseph P. Gaut3, Prabha Ranganathan1,
Anitha Vijayan4
1Department of Medicine, Division of Rheumatology, Washington University School of Medicine,
2Department of Medicine, Division of Pulmonary and Critical Care, Washington University School
of Medicine, 3Department of Pathology and Immunology, Division of Anatomic and Molecular
Pathology, Washington University School of Medicine, 4Department of Medicine, Division of
Nephrology, Washington University School of Medicine, St. Louis, MO, USA
ABSTRACT. Hydralazine is a commonly used anti-hypertensive medication. It can, however,
contribute to the development of autoimmunity, in the form of drug-induced lupus and anti-
neutrophil cytoplasmic antibodies-associated vasculitis. We report a 45-year-old patient with
hypertension managed with hydralazine for four years who presented with rapidly progressive
glomerulonephritis (RPGN), requiring hemodialysis, and diffuse alveolar hemorrhage (DAH),
requiring mechanical ventilation, and extracorporeal membrane oxygenation. The patient’s
autoantibody profile was consistent with a drug-induced autoimmune process and renal histology
revealed focal necrotizing crescentic GN. She was treated with high-dose steroids, plasma
exchange and rituximab. DAH resolved and her renal function improved, allowing discontinua-
tion of hemodialysis. This case reveals that rituximab can be successfully used in the setting of
hydralazine-induced vasculitis, including critically ill patients with severe DAH and acute kidney
injury from RPGN.
Introduction
Hydralazine is a commonly used medication
in the treatment of hypertension through induc-
tion of peripheral vasodilation through relaxa-
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tion of vascular smooth muscle. Hydralazine is
often utilized in patients with difficult to treat
hypertension and congestive heart failure as it
confers survival benefit in the latter group.1 It
can, however, contribute to the development
of autoimmunity, in the form of drug-induced
lupus (DIL) and anti-neutrophil cytoplasmic
antibodies (ANCA)-associated vasculitis (AAV).
Hydralazine-induced DIL was described within
the first several years of its introduction into
clinical practice.2-4 DIL from hydralazine is
characterized by positive anti-nuclear anti-




[Downloaded free from http://www.sjkdt.org on Thursday, March 14, 2019, IP: 128.252.119.61]
stranded DNA (dsDNA) antibodies.5 While the
mechanism underlying DIL remains unclear, it
has been previously suggested to arise from
cytotoxic metabolites generated by myeloper-
oxidase (MPO) in immune cells.6
In contrast to DIL, AAV is a rare but serious
adverse event from hydralazine that manifests
primarily as glomerulonephritis with skin,
joint and lung involvement.5 Hydralazine-
induced AAV is associated with a positive
ANA, anti-histone antibodies, ANCA, and
high-titer anti-MPO antibodies.5,7,8 In addition,
dsDNA antibodies have been reported in 26%
of cases of hydralazine-induced AAV.5 The
presence of multi-antigenicity in drug-induced
vasculitis is not fully understood but may be
due to drug-induced modifications of MPO
granules and subsequent death of neutrophils,
leading to exposure of multiple neutrophil
auto-antigens from neutrophil extracellular
traps.6,9 Awareness of this unusual drug toxi-
city is important to enable prompt diagnosis
and appropriate treatment.
Rituximab is a monoclonal antibody to CD20
that depletes B cells and has been shown to be
as efficacious as cyclophosphamide in the
treatment of AAV.10 However since the initial
trials did not enroll patients with respiratory
failure or on dialysis, there has been some
reluctance to embrace treatment with ritu-
ximab in settings of severe AAV.11 We present
a case of life-threatening hydralazine-induced
AAV that was successfully treated with ritu-
ximab in a patient that was treated with hydra-
lazine for four years.
Case Report
A 45-year-old African–American female with
Marfan’s syndrome and hypertension presented
with three weeks of sharp chest pain, radiating
to the back, left arm, and abdomen. She was
on hydralazine, which had been increased over
the last four years to 100 mg TID. Blood
pressure was 210/107 with a heart rate of 47.
Initial serum creatinine was 1.9 mg/dL (prior
baseline 0.9), which corresponded to an
estimated glomerular filtration rate (calculated
with modification of diet in renal disease
MDRD) of 35 mL/min/1.73 m2. Urinalysis
showed specific gravity >1.030, protein 4+,
blood 3+, leukocyte 1+. Automated urine
microscopy revealed 20–50 white blood cells/
hpf and >50 red blood cells (RBCs)/hpf. She
received prochlorperazine for nausea, which
led to oropharyngeal angioedema complicated
by cardiac arrest with successful resuscitation.
A computerized tomography angiogram revealed
a type B dissection spanning the entire descen-
ding aorta. She underwent percutaneous endo-
vascular repair of the aorta with stent place-
ment. Postoperatively, she developed anuria
and serum creatinine rose to 4.3 mg/dL. Urine
microscopy by the nephrology service revealed
dysmorphic RBCs and no granular casts. She
was started on emergent hemodialysis.
ANA and ANCA were positive at 1:320
(speckled pattern) and 1:1280 (p-ANCA)
respectively. Further workup showed positive
SSA, dsDNA (255 IU/mL), anti-histone (4.9U),
and anti-MPO (98U) antibodies, and low C3
(71 mg/dL). Antibodies to proteinase three and
glomerular basement membrane were nega-
tive. Renal biopsy was performed and patho-
logy showed pauci-immune diffuse necrotizing
crescentic glomerulonephritis (Figure 1).
She was diagnosed with hydralazine-induced
AAV (Table 1). She was treated with methyl-
prednisolone 1 g intravenous (IV) for three
days followed by oral prednisone 1 mg/kg/day.
On day 4 of oral prednisone, frank blood was
noted in her endotracheal tube. She became
hypoxemic despite maximum ventilatory sup-
port and was started on ECMO. Chest X-ray
revealed bilateral lung opacities consistent
with diffuse alveolar hemorrhage (DAH). She
underwent plasma exchange for six cycles
followed by two doses of rituximab, 1 g IV,
two weeks apart.
The patient remained ECMO-dependent for
three weeks. After a five-week intensive care
unit stays, she underwent a prolonged hospital-
lization and rehabilitation for sepsis, fungemia,
gastrointestinal bleeding, wound infection,
neuropathy, and myopathy. Her tracheostomy
was decannulated after six weeks and dialysis
was discontinued after eight weeks. Her renal
function improved to near baseline after three
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months and serum creatinine stabilized at 1.1
mg/dL after six months.
Discussion
This case illustrates three salient points. One,
this patient’s acute kidney injury (AKI) could
have been attributed to multifactorial ischemic
and toxic acute tubular necrosis (ATN) from
radiographic IV contrast, transcutaneous aortic
repair and hypotension from cardiac arrest.
However, the presence of dysmorphic RBCs
without granular casts on urine microscopy
suggested glomerulonephritis and led to a
renal biopsy with a diagnosis of hydralazine-
induced AAV. This reiterates the importance
of examining the urine sediment in patients
with AKI.12 Kidney biopsy should be pursued
in unexplained causes of AKI if urine sediment
does not indicate ATN since treatment and
prognosis vary significantly between different
etiologies. In a patient with ATN, approxi-
mately 75% of patients who survive hospita-
lization may recover renal function in about 60
days.13 For patients with RPGN, the prognosis
for renal recovery is guarded, especially with
severe crescentic lesions on renal pathology.
However, aggressive care with immunosup-
pression and plasma exchange can improve
renal survival as demonstrated by the MEPEX
trial.14 Two, hydralazine induced vasculitis,
although uncommon, occurs. Hydralazine-
associated autoimmunity is a dose-dependent
phenomenon that often presents as DIL.15 A
Figure 1. Renal biopsy in a patient with hydralazine-induced ANCA associated vasculitis. (a). Light
microscopic examination with Hematoxylin and Eosin stain demonstrating segmental necrotizing
glomerulonephritis with obliteration of the capillary lumen by fibrinous material (arrow). (b) Periodic
acid–Schiff stain demonstrating cellular crescents (arrowhead) (×40).
Table 1. Distinct teaching points about hydralazine-induced ANCA associated vasculitis.
Distinct teaching points
 Hydralazine-induced ANCA-associated vasculitis is associated with multiple autoantibodies: ANA,
ANCA, anti-histone, high-titer anti-MPO antibodies and occasionally anti-dsDNA antibodies.
 Examination of urine sediment is essential to establishing the etiology of acute kidney injury, even
in the setting of nephrotoxic agents or hypoperfusion.
 Rituximab can be an effective therapy for hydralazine-induced ANCA-associated vasculitis
including life-threatening disease.
 ECMO can be an effective therapy for respiratory failure due to hydralazine-induced ANCA-
associated vasculitis until the benefits of immunosuppression manifest.
 A clinical benefit of Rituximab may take up to 3 weeks to become apparent in ANCA-associated
vasculitis.
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less common, but life-threatening manifesta-
tion is AAV.5 Unlike DIL, where discontinuation
of hydralazine is often sufficient, hydralazine-
induced AAV often requires aggressive immu-
nosuppression.5 Given the lack of experience
with rituximab in hydralazine-induced AAV,
cyclophosphamide is still recommended as
first-line therapy.16 This case demonstrates that
rituximab can be an effective therapeutic
option for hydralazine-induced AAV.
Third, some clinicians avoid the use of
rituximab in critically-ill patients, for example,
DAH requiring mechanical ventilation or
serum Cr >4 mg/dL, based on the RAVE trial
which excluded such patients.10 This patient
would have been excluded from the RAVE
trial due to both DAH and her serum Cr.
Accordingly, the Kidney Disease: Improving
Global Outcome (KDIGO) guidelines from
2012 recommend using cyclophosphamide with
steroids as the initial treatment for severe
pauci-immune focal and segmental necrotizing
glomerulonephritis. KDIGO further recom-
mends that rituximab with steroids can be used
as an alternative initial treatment in patients
without severe disease or in whom cyclophos-
phamide is contraindicated.17 In contrast, the
Kidney Disease Outcomes Quality Initiative
commentary on the KDIGO guidelines sugges-
ted that rituximab be considered as equivalent
to cyclophosphamide in the initial treatment of
severe disease.18 In support of this recommen-
dation, several recent retrospective reports
suggest that rituximab can be clinically effica-
cious in the setting of severe AAV.19,20 While
these multicenter studies were small (only 14
and 37 cases), they demonstrated comparable
rates of dialysis independence compared to the
RAVE trial despite a more severe clinical
presentation (MDRD eGFR of ≤20 mL/min/
1.73 m2). Similarly, rituximab was effectively
used in this patient in the setting of life-
threatening hydralazine-induced AAV.
Conclusion
Hydralazine-induced autoimmunity can be
severe and potentially life-threatening. To our
knowledge, this is the first report of successful
use of rituximab and ECMO to treat
hydralazine-induced AAV and highlights their
therapeutic efficacy in this condition. A high
degree of vigilance is required to recognize
and treat this serious complication of a com-
monly used medication.
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